- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
- Fate Therapeutics to Present at Upcoming March Investor Conferences
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
- Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Wednesday, Fate Therapeutics Inc (FATE:NMQ) closed at 4.30, 163.80% above the 52 week low of 1.63 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.59 |
---|---|
High | 4.66 |
Low | 4.17 |
Bid | 4.20 |
Offer | 4.88 |
Previous close | 4.54 |
Average volume | 2.41m |
---|---|
Shares outstanding | 113.17m |
Free float | 111.51m |
P/E (TTM) | -- |
Market cap | 513.80m USD |
EPS (TTM) | -1.63 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼